CN110494142A - 癌症治疗 - Google Patents

癌症治疗 Download PDF

Info

Publication number
CN110494142A
CN110494142A CN201880019933.1A CN201880019933A CN110494142A CN 110494142 A CN110494142 A CN 110494142A CN 201880019933 A CN201880019933 A CN 201880019933A CN 110494142 A CN110494142 A CN 110494142A
Authority
CN
China
Prior art keywords
pharmaceutical composition
methyl
inhibitor
daily dose
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880019933.1A
Other languages
English (en)
Chinese (zh)
Inventor
P·F·戴维斯
T·一廷唐
R·W·麻石
S·T·谈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gillis Mckinder Institute
Original Assignee
Gillis Mckinder Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gillis Mckinder Institute filed Critical Gillis Mckinder Institute
Publication of CN110494142A publication Critical patent/CN110494142A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880019933.1A 2017-01-31 2018-01-31 癌症治疗 Pending CN110494142A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762452479P 2017-01-31 2017-01-31
US62/452,479 2017-01-31
PCT/NZ2018/050006 WO2018143826A1 (en) 2017-01-31 2018-01-31 Cancer therapeutic

Publications (1)

Publication Number Publication Date
CN110494142A true CN110494142A (zh) 2019-11-22

Family

ID=63040946

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880019933.1A Pending CN110494142A (zh) 2017-01-31 2018-01-31 癌症治疗

Country Status (7)

Country Link
US (2) US20200197335A1 (enExample)
EP (1) EP3576746A4 (enExample)
JP (2) JP2020515523A (enExample)
CN (1) CN110494142A (enExample)
AU (2) AU2018215857A1 (enExample)
CA (1) CA3051840A1 (enExample)
WO (1) WO2018143826A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113069443A (zh) * 2021-04-12 2021-07-06 四川大学 奈必洛尔在制备预防和/或治疗口腔白斑及口腔鳞状细胞癌的药物中的用途
CN115843246A (zh) * 2020-01-29 2023-03-24 吉利斯麦金德研究院 用于治疗血管瘤的方法和组合物
CN116963724A (zh) * 2021-03-03 2023-10-27 萨恩帕斯药物有限公司 用于人类恶性胸腔积液的治疗

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020027665A1 (en) * 2018-07-30 2020-02-06 Gillies Mcindoe Research Institute Novel pharmaceutical compositions for cancer therapy
WO2020135920A1 (en) * 2018-12-28 2020-07-02 Université Libre de Bruxelles Kit for inhaled chemotherapy, and treatment of lung cancer with said kit

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077394A1 (en) * 2004-02-11 2005-08-25 Ramot At Tel-Aviv University Ltd Compositions for treatment of cancer and inflammation with curcumin and at least one nsaid
WO2016004218A1 (en) * 2014-07-01 2016-01-07 Vicus Therapeutics, Llc Combination drug therapies for cancer and methods of making and using them
WO2016024870A1 (en) * 2014-08-12 2016-02-18 Gillies Mcindoe Research Institute Cancer diagnosis and therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016054511A1 (en) * 2014-10-02 2016-04-07 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of aging-associated dysfunction of stem cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077394A1 (en) * 2004-02-11 2005-08-25 Ramot At Tel-Aviv University Ltd Compositions for treatment of cancer and inflammation with curcumin and at least one nsaid
WO2016004218A1 (en) * 2014-07-01 2016-01-07 Vicus Therapeutics, Llc Combination drug therapies for cancer and methods of making and using them
WO2016024870A1 (en) * 2014-08-12 2016-02-18 Gillies Mcindoe Research Institute Cancer diagnosis and therapy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
SAHDEO PRASAD等: "Recent Developments in Delivery, Bioavailability, Absorption and Metabolism of Curcumin: the Golden Pigment from Golden Spice", 《CANCER RESEARCH AND TREATMENT》, vol. 46, no. 1, pages 2 - 18, XP055427457, DOI: 10.4143/crt.2014.46.1.2 *
SAHDEO PRASAD等: "Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spiceRecent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice", 《CANCER RESEARCH AND TREATMENT》 *
SAHDEO PRASAD等: "Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spiceRecent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice", 《CANCER RESEARCH AND TREATMENT》, vol. 46, no. 1, 31 December 2014 (2014-12-31), pages 2 - 18, XP055427457, DOI: 10.4143/crt.2014.46.1.2 *
V. C. MIRANDA等: "Exploring the role of metformin in anticancer treatments: a systematic review", 《DRUGS OF TODAY》 *
V. C. MIRANDA等: "Exploring the role of metformin in anticancer treatments: a systematic review", 《DRUGS OF TODAY》, vol. 50, no. 9, 31 December 2014 (2014-12-31), pages 623, XP055719061, DOI: 10.1358/dot.2014.50.9.2229920 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115843246A (zh) * 2020-01-29 2023-03-24 吉利斯麦金德研究院 用于治疗血管瘤的方法和组合物
CN116963724A (zh) * 2021-03-03 2023-10-27 萨恩帕斯药物有限公司 用于人类恶性胸腔积液的治疗
CN113069443A (zh) * 2021-04-12 2021-07-06 四川大学 奈必洛尔在制备预防和/或治疗口腔白斑及口腔鳞状细胞癌的药物中的用途

Also Published As

Publication number Publication date
EP3576746A4 (en) 2020-09-09
AU2024200098A1 (en) 2024-01-25
US20200197335A1 (en) 2020-06-25
AU2018215857A1 (en) 2019-08-15
WO2018143826A1 (en) 2018-08-09
JP2023075272A (ja) 2023-05-30
JP2020515523A (ja) 2020-05-28
US20230364037A1 (en) 2023-11-16
EP3576746A1 (en) 2019-12-11
CA3051840A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
US20230364037A1 (en) Cancer therapeutic
JP6926065B2 (ja) 癌を治療するための方法
TWI844512B (zh) 用於治療非轉移性去勢抗性前列腺癌之抗雄性激素
Aldea et al. Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery
JP2017078085A (ja) 併用療法
CA2758820C (en) Targeted sustained-release microsphere of vascular occlusive agent containing sodium alginate and sorafenib, production method and use thereof
KR20190130050A (ko) 췌장암의 치료 방법
AU2016285597A1 (en) Combination of HDAC inhibitor and anti-PD-L1 antibody for treatment of cancer
RU2640180C2 (ru) Способ адъювантного лечения рака
US20240180906A1 (en) Combination of Talazoparib and an Anti-Androgen for the Treatment of DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer
EP0996461B1 (en) Use of a complement activation inhibitor in the manufacture of a medicament for inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
KR20200013644A (ko) 간세포 암종의 치료
US20130011480A1 (en) Cytotoxic therapy by proton flux modulation
WO2020027665A1 (en) Novel pharmaceutical compositions for cancer therapy
WO2024127140A1 (en) Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
Guardiola et al. Intraoperative chemotherapy with cisplatin and epinephrine after cytoreductive surgery in patients with recurrent ovarian cancer: a phase I study
Jackson et al. Therapeutic options in gastric cancer: neoadjuvant chemotherapy vs postoperative chemoradiotherapy
CN108883106A (zh) 使用了乐伐替尼和依维莫司的肾细胞癌治疗
Scanga et al. Sorafenib: A glimmer of hope for unresectable hepatocellular carcinoma?
JP2023538186A (ja) 化学療法誘発性下痢を治療するための方法及び組成物
JP2015515971A (ja) うつ病を治療するためのトラマドール
Chipiti et al. Clinical trials and research advances in colorectal treatment resistance
Salemis Rivaroxaban-induced chest wall spontaneous expanding hematoma
Wang et al. The combined use of PD-1 antibodies and anti-angiogenic TKIs induces intractable thoracoabdominal wall ulcer in patients undergoing cryoablation for superficial metastases of hepatocellular carcinoma
JP2024157057A (ja) バレット食道の治療用組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191122

WD01 Invention patent application deemed withdrawn after publication